- £81.91bn
- £95.80bn
- £32.67bn
REG - GlaxoSmithKline PLC - FDA approves GSK’s JEMPERLI (dostarlimab-gxly)
AnnouncementREG - GlaxoSmithKline PLC - Director/PDMR Shareholding
AnnouncementREG - GlaxoSmithKline PLC - Director/PDMR Shareholding
AnnouncementREG - GlaxoSmithKline PLC - Director/PDMR Shareholding
AnnouncementREG - GlaxoSmithKline PLC - Director/PDMR Shareholding
AnnouncementREG - GlaxoSmithKline PLC - Director/PDMR Shareholding
AnnouncementREG - GlaxoSmithKline PLC - Director/PDMR Shareholding
AnnouncementREG - GlaxoSmithKline PLC - Director/PDMR Shareholding
AnnouncementREG - GlaxoSmithKline PLC - Director/PDMR Shareholding
AnnouncementREG - GlaxoSmithKline PLC - Director/PDMR Shareholding
AnnouncementREG - GlaxoSmithKline PLC - Directorate Change
AnnouncementREG - GlaxoSmithKline PLC - Total Voting Rights
AnnouncementREG - GlaxoSmithKline PLC - Publication of 2021 AGM Notice
AnnouncementREG - GlaxoSmithKline PLC - GSK respiratory product sales reporting changes
AnnouncementREG - GlaxoSmithKline PLC - Moncef Slaoui Departs Galvani Bioelectronics
AnnouncementREG - GlaxoSmithKline PLC - Director/PDMR Shareholding
AnnouncementREG - GlaxoSmithKline PLC - Chair of Audit & Risk Committee
AnnouncementREG - GlaxoSmithKline PLC - Medicago and GSK start Phase 3 trial
AnnouncementREG - GlaxoSmithKline PLC - Director/PDMR Shareholding
Announcement